Implantable device for the delivery of histrelin and methods of use thereof
AssigneeEndo Pharmaceuticals Solutions Inc.
InventorsPetr Kuzma, Harry Quandt
Life of this patent
Estimating the term…
Abstract
This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs.
Claims12
A method for delivering a formulation comprising an effective amount of histrelin to a subject, comprising:
- implanting an implantable device into the subject, wherein the implantable device comprises histrelin substantially surrounded by a polyurethane-based polymer, wherein the polyurethane-based polymer is a Tecophilic® polymer with an equilibrium water content of at least about 31%.
A method for delivering a formulation comprising an effective amount of histrelin to a subject, comprising:
- implanting an implantable device into the subject, wherein the implantable device comprises histrelin substantially surrounded by a polyurethane-based polymer, wherein the polyurethane-based polymer is a Tecoflex® polymer with a flex modulus of about 10,000.
A method for delivering a formulation comprising an effective amount of histrelin to a subject, comprising:
- implanting an implantable device into the subject, wherein the implantable device comprises histrelin substantially surrounded by a polyurethane based polymer, wherein the polyurethane-based polymer is a Carbothane® polymer with a flex modulus of about 4,500.
A drug delivery device for the controlled release of histrelin over an extended period of time to produce local or systemic pharmacological effects, comprising:
- a) a polyurethane-based Tecophilic® polymer with an equilibrium water content of at least about 31% formed to define a hollow space;
- and
- b) a solid drug formulation comprising a formulation comprising histrelin and optionally one or more pharmaceutically acceptable carriers,
- wherein the solid drug formulation is in the hollow space, and wherein the device provides a desired release rate of histrelin from the device after implantation.
A drug delivery device for the controlled release of histrelin over an extended period of time to produce local or systemic pharmacological effects, comprising:
- a) a polyurethane-based Tecoflex® polymer with a flex modulus of about 10,000 formed to define a hollow space;
- and
- b) a solid drug formulation comprising a formulation comprising histrelin and optionally one or more pharmaceutically acceptable carriers,
- wherein the solid drug formulation is in the hollow space, and wherein the device provides a desired release rate of histrelin from the device after implantation.
A drug delivery device for the controlled release of histrelin over an extended period of time to produce local or systemic pharmacological effects, comprising:
- a) a polyurethane-based Carbothane® polymer with a flex modulus of about 4,500 formed to define a hollow space;
- and
- b) a solid drug formulation comprising a formulation comprising histrelin and optionally one or more pharmaceutically acceptable carriers,
- wherein the solid drug formulation is in the hollow space, and wherein the device provides a desired release rate of histrelin from the device after implantation.
Dependencies are inferred from the claim text.